IP Library › Granted Patent US 12,383,544
Granted Patent B2
US 12,383,544 · App. 17/605,623 · Granted Aug 12, 2025

Methods for the treatment of polycystic kidney disease

Inventors: Katja Els Conrath (Mechelen, BE); Reginald Christophe Xavier Brys (Mechelen, BE); Thierry Jean-Claude Marie Christophe (Mechelen, BE); Ronald Van Der Geest (Tilburg, NL)
Assignee: Galapagos NV
A61K31/4545A61K31/155A61K31/55A61K45/06A61P13/12C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,544
App. No.
17/605,623
Granted
Aug 12, 2025
Kind
B2
Abstract

The present invention discloses compounds according to Formula I: Wherein R 1 is as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of that may be useful in the prophylaxis and/or treatment of polycystic kidney disease (PKD), by administering the compound of the invention.

Claims (18)

1. A method of prophylaxis and/or treatment of a mammal afflicted with polycystic kidney disease, comprising administering an effective amount of a compound according to Formula (I):

wherein R 1 is H or —CH 3 ;

or a pharmaceutically acceptable salt, or a solvate or the pharmaceutically acceptable salt of a solvate thereof, to the mammal.

2. The method according to claim 1 , wherein R 1 is H.

3. The method according to claim 1 , wherein R 1 is —CH 3 .

4. The method according to claim 1 , wherein the polycystic kidney disease is autosomal dominant polycystic kidney disease.

5. A method of prophylaxis and/or treatment of a mammal afflicted with polycystic kidney disease, comprising administering a pharmaceutical composition comprising a compound or pharmaceutically acceptable salt according to claim 1 , and a pharmaceutically acceptable carrier, to the mammal.

6. The method according to claim 5 , comprising administering a further therapeutic agent to the mammal.

7. The method according to claim 6 , wherein the further therapeutic agent is a polycystic kidney disease treatment agent.

8. The method according to claim 6 , wherein the further therapeutic agent is tolvaptan.

9. The method according to claim 6 , wherein the further therapeutic agent is Metformin.

10. The method according to claim 5 , wherein the polycystic kidney disease is autosomal dominant kidney disease.

11. The method according to claim 5 , wherein R 1 is H.

12. The method according to claim 5 , wherein R 1 is —CH 3 .

13. The method according to claim 1 , comprising administering a further therapeutic agent to the mammal.

14. The method according to claim 13 , wherein the further therapeutic agent is a polycystic kidney disease treatment agent.

15. The method according to claim 13 , wherein the further therapeutic agent is tolvaptan.

16. The method according to claim 13 , wherein the further therapeutic agent is Metformin.

Assignments (4)
CHANGE OF NAME Recorded Jun 4, 2026
From: GALAPAGOS
To: LAKEFRONT BIOTHERAPEUTICS
Reel/Frame 074845/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: CONRATH, KATJA ELS; BRYS, REGINALD CHRISTOPHE XAVIER; CHRISTOPHE, THIERRY JEAN-CLAUDE MARIE
To: GALAPAGOS NV
Reel/Frame 058748/0110 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: VAN DER GEEST, RONALD
To: 3D-PHARMXCHANGE B.V.
Reel/Frame 058748/0139 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2022
From: 3D-PHARMXCHANGE B.V.
To: GALAPAGOS NV
Reel/Frame 058748/0173 →
Priority Claims (1)
GB 1905711 · Apr 24, 2019 · national
Continuity (1)
Related Publication 20220202802A1 · Jun 30, 2022
References Cited (18)
US 20090197911A1 · Georg et al. · 2009 [cited by applicant]
WO 2011019737A1 · 2011 [cited by applicant]
WO 2013180310A1 · 2013 [cited by applicant]
WO 2016073470A1 · 2016 [cited by applicant]
WO 2017060879A · 2017 [cited by applicant]
WO WO2017060874A1 · 2017 [cited by examiner]
WO 2018237174A2 · 2018 [cited by applicant]
Rysz et al., Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease, Exp. Op. Pharmacother., 17, pp. 2049-2056 (Year: 2016). [cited by examiner]
Yang et al., Small-Molecule CFTR Inhibitors Slow Cyst Growth in Polycystic Kidney Disease, J. Am. Soc. Nephrol., 19, pp. 1300-1310 (Year: 2008). [cited by examiner]
Torres V.E. et al, “Autosomal dominant polycystic kidney disease”, The Lancet, 2007, vol. 369, No. 9569, pp. 1287-1301. [cited by applicant]
Yang B. et al., “Small-Molecule CFTR Inhibitors Slow Cyst Growth in Polycystic Kidney Disease”, J. Am. Soc. Nephrol. JASN, 2008, vol. 19, No. 7, pp. 1300-1310. [cited by applicant]
Torres V.E., “Treatment Strategies and Clinical Trial Design in ADPKD”, Adv. Chronic Kidney Dis., 2010, vol. 17, No. 2, pp. 190-204. [cited by applicant]
Thiagarajah J.R. et al., “CFTR Inhibitors for Treating Diarrheal Disease”, Clin. Pharmacol. Ther., 2012, vol. 92, No. 3, pp. 287-290. [cited by applicant]
Galietta L.V.J. et al., “Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists”, Am. J. Physiol.-Cell Physiol., 2001, vol. 281, No. 5, pp. C1734-C1742. [cited by applicant]
Fulcher M.L. et al., “Well-differentiated human airway epithelial cell cultures”, Methods Mol. Med., 2005, vol. 107, pp. 183-206. [cited by applicant]
Booij T. H. et al., “High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease,” SLAS Discov. Adv. Life Sci. RD, 2017, vol. 22, No. 8, pp. 974-984. [cited by applicant]
Lee, Edmund C. et al. 2019. “Discovery and Preclinical Evaluation of Anti-MIR-17 Oligonucleotide RGLS4326 for the Treatment of Polycystic Kidney Disease,” Nature Communications 10 (1): 4148. [cited by applicant]
International Search Report and Written Opinion Issued on Jun. 10, 2020 in PCT/EP2020/061083. [cited by applicant]